Barclays’s Immix Biopharma IMMX Stock Holding History

Barclays’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$547K	Buy	53,056 +1,288	+2%	+$11.9K	﹤0.01%	3159
2026 Q1	$472K	Buy	51,768 +16,768	+48%	+$123K	﹤0.01%	3222
2025 Q4	$183K	Buy	+35,000	New	+$144K	﹤0.01%	4363

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's IMMX Position: Q2 2026 in Review

Barclays increased its Immix Biopharma (IMMX) stake by 2.5% in Q2 2026, buying an estimated $11.9K and bringing the position to 53,056 shares worth $547K. The position accounts for ﹤0.01% of the portfolio, ranked #3159.

Barclays first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Barclays held 53,056 shares of Immix Biopharma worth $547K as of Q2 2026.
Barclays bought 1,288 Immix Biopharma shares in Q2 2026, an estimated $11.9K.
Immix Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3159 holding.
Barclays first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.